Short answer
Sana Biotechnology, Inc. (SANA) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$42M
- +29.7% YoY · +55.1% QoQ
- EPS (diluted)
- −$0.15
- +40.0% YoY · +61.5% QoQ
Source: XBRL data from the Sana Biotechnology, Inc. (SANA) Q3 2025 10-Q on SEC EDGAR. USD.
Sana Biotechnology, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly emphasized regulatory risk: FDA class-wide CAR T boxed warning for T-cell malignancies, raising potential requirements for in vivo CAR T therapies
- Most materially updated technology risk: portfolio prioritization suspended two allogeneic CAR T programs and concentrated development on SC451 and fusogen-enabled programs
- Clinical safety risk: gene editing may cause off-target edits, DNA rearrangements, or genotoxicity associated with genome-modifying payloads
- Operational risk: manufacturing complexity and CDMO dependence could delay clinical supply or commercial production
- Financial risk: continued significant losses and no approved products require additional funding, potentially delaying or eliminating development programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sana Biotechnology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.